Method of estimating efficiency of neoadjuvant autohemochemotherapy in patients suffering from carcinoma of cervival stump |
|||||||||||||||||||||||||||||
|
IPC classes for russian patent Method of estimating efficiency of neoadjuvant autohemochemotherapy in patients suffering from carcinoma of cervival stump (RU 2375063):
Method of determining effeciency of larynx cancer treatment / 2375003
Invention relates to medicine, namely to oncology and can be applied in presence of locally advanced process. In daily urine of patients before treatment tetrahydro-11-desoxycortisol is determined. If its level before treatment does not exceed 2 mcmol/day relapse-free period is forecasted during 2 and more years; initial level of fraction over 2 mcmol/day indicates about disease relapse or metastases during first year after treatment.
Way of forecasting of restoration of menstrual function at patients with nervous anorexia / 2363002
Invention concerns medicine, namely to gynecology, and can be used at treatment of patients with amenorrhea caused by nervous anorexia. Level of leptin is defined in blood serum using enzyme immunoassay method for realisation of the way of forecasting of restoration of menstrual function at patients with a nervous anorexia. Then an index of mass of a body (BMI) and a parity leptin/BMI is counted. In case the parity leptin/BMI makes 0.8 and more - normalisation of menstrual function is prognosticated.
Way of diagnostics of male sterility / 2362167
Invention concerns medicine area, namely to andrology, and concerns diagnostics of male sterility. The way includes studying compaction degree of chromatin of spermatozoids, percentage of defective cells in an ejaculate, level of B in blood serum. On the basis of the received data diagnostic index DI is calculated; its value helps to diagnose sterility, or absence of pathology.
 Method of diagnosing functional hyperprolactinaemia in girls / 2351935
In girls with suspected functional hyperprolactinaemia determined are level of prolactin two hours after falling asleep, concentration of general triiodtrionin, cortisol, and ultra-sound examination of small pelvis organs is carried out in order to determine volume of right ovary. On the basis of obtained data canonical value (K) is calculated by formula, and if K is greater than (-2.28) and lower than 1.27 functional hyperprolactinaemia is determined.
 Method of diagnosing hormonally inactive microadenomas of hypophysis in girls / 2351934
Invention can be used for diagnosing hormonally inactive microadenomas of hypophysis (IAH) in girls. In order to realise the method levels of prolactin in blood is determined in girls with suspected two hours after falling asleep and at 6 o'clock in the morning. On the basis of obtained data, canonical value (K) is calculated by formula, and if K is greater than (-1.69) and smaller than 1.86 IAH is diagnosed.
Method of determination of orientation of pathological process at cancer of ovaries / 2350966
Invention concerns medicine, namely to onco-gynecology. The essence of the method consists in the following: level of Testosteron is defined and at its content peer or above 2.5 nmol/l, intraoperative in blood of women with tumorous formations of ovaries before operation. In a tissue of a tumour of ovaries the maintenance of Testosteron is defined and at augmentation of its indicator above 2 nmol/g operation of full volume is carried out.
 Evaluation method for perioperative stress and quality of organism nociceptive protection / 2342669
Invention relates to medicine, namely surgery and anesthesiology, and refers to evaluation method for perioperative stress and quality of organism nociceptive protection. The method consists in radioimmunoassay of cortisol content in daily urine before and after the operation, beginning with first post-operative urine portion, and finishing with next day morning urine. If cortisol concentration has grown twice and higher, then inadequate organism protection from operative stress and post-operative pain syndrome is stated.
 Method of predicting of life expectancy of patients with local cancer of prostate / 2341197
Define risk factors from the anamnesis of a life and clinico-laboratory indicators: the age, degree of differentiation of a tumour, level of Testosteron-Depotum and prostates-specific antigen in blood serum (PSA), carry on prediction depending on their values, thus in addition define time from the development of hormone-resistance beginning, estimate level of painful sensations and the general condition of the patient on scale ECOG, define degree of disturbance of an emiction on international IPSS scale, establish gradation and numerical value of risk factors then define life expectancy of the patient in months under the formula: Y=-9.17+0.47•X1+1.94•X2-0.698•X3+0.01•X4 2+0.07•X3 2-1.66•X5 2+1.86•X6 2-0.0003•X7 2+0.01•X8 2, where: Y - life expectancy of the patient in months; X1, 2...8 - gradation and numerical value of risk factors, and X1 - age, years; X2 - tumour differentiation: G0 - low-grade tumour =0, G1 differentiated tumour =1, G2 - moderate-grade tumour =2, G3 - a low-grade tumour =3, G4 - an undifferentiated tumour =4; X3 - Testosteron-Depotum level in ng/ml; X4 - time from the beginning of hormone-resistance development in months; X5 - level of painful sensations of the patient: absence of pain =0, mild pain =1, moderate pain d-2, strong pain =3, intolerable pain =4; X6 - general condition of the patient on ECOG scale: activity of the patient is unlimited =0, restriction by kinds of activity of demanding efforts =1, walking and capable itself to serve, but incapable to perform any work =2, is limited capable for Self-Care =3, completely incapable of any activity =4; X7 - level of the PSA in ng/ml; X8 - degree of disturbance of an emiction at patients on international scale IPSS (from 0 to 36 points).
Method of diagnostics of vibration sickness degree / 2337363
Invention concerns medicine and can be used for definition of degree of expression of vibration sickness. For realisation of the method perform determination of blood rheumatic factor and antibodies to cardiolipin, phagocytic activity of blood, level of CD-4+- and CD-16 of +-lymphocytes, M immunoglobulin (Ig M) and cytokine IL-10 (IL-10), adrenocorticotropic and thyritropic hormones ("АКТГ" and "ТТГ") in the blood. Define prognostic factors F1 and F2 and compare them on the basis of the obtained data. In case if F1 it is higher than F2, diagnose vibration sickness of I degree, and if F1 is less than F2 - vibratory illness of II degree.
Method of provided efficiency of non-adjuvant autohemochemotherapy for patients suffering from paget-type breast cancer / 2328747
Patient's blood is tested prior to and after radioimmunotherapy for contents of progesterone, estradiol, follicle- and lutein-stimulating hormones. Patients after treatment are diagnosed with increased progesterone amount from 1.50 to 4.7 nmole/l, reduced ratio of follicle-stimulating to lutein-stimulating hormones from 0.88 to 0.32 and reduced ratio of estradiol to progesterone from 208 to 117, and tumour regression is diagnosed with reduction of progesterone from 0.95-1.34 nmole/l to 0.41-0.83, increased ratio of follicle-stimulating to lutein-stimulating hormones from 0.83-3.81 to 2.07-4.41 and reduced ratio of estradiol to progesterone from 205.2-328.4 to 255.8-671.1.
Improved photosensibiliser compositions and their application / 2371181
Invention concerns photodynamic therapy (PDT) and claims composition with low concentration of hydrophobic photosensibilisers (PS) and improved method of PDT. In the claimed composition, given PS, meta-tetrahydroxyphenylchlorine (m-THPC) is present in concentration of 0.8 mg/ml to 0.04 mg/ml in the mix of pure ethyleneglycol and ethanol at 3:2 ratio. Composition reduces therapeutic effect accumulation time for the PS in affected tissue and time of achieving sufficient PS ratio in comparison to healthy tissue. Application of composition with m-THPC PS reduces interval between PS application/injection and irradiation. PS diffusion between affected and normal tissues can proceed fast enough for introduction in 'one day' or one night time. Claimed composition can be applied for PDT regimens where photosensibilisers are introduced in at least one prearranged dosage, including low-concentration therapy for PDT.
 Water-soluble anion-containing bacteriochlorophyll derivatives of and their application / 2353624
Invention relates to field of biotechnology, namely to bacteriochlorophyll derivatives and can be used for medical and diagnostic purposes. Anion-containing water-soluble tetracyclic and pentacyclic bacteriochlorophyll (Bchl) derivatives contain one, two or three negatively charged groups and/or acid groups, which transform into negatively charged groups at physiological pH. Obtained derivatives are used for photodynamic therapy and for tumor diagnostics, as well as for killing cells or infectious agents.
 Covalent conjugants between endoperoxides related to artemizinin and ferriferous proteins and methods of application / 2325156
Invention is a covalent conjugant or endoperoxyde related to artemizinin and ferriferous protein.
 Injectable galenic composition for using in diagnosis or photodynamic therapy and method for its preparing / 2278665
Invention relates to the injectable galenic composition used in diagnosis or photodynamic therapy and to a method for its preparing. The composition comprises the following components: compound of the general formula (I) given in the invention description wherein R2 means hydrogen atom, hydroxyl group (-OH) or group -COOR4 wherein R4 means hydrogen atom or (C1-C12)-alkyl, or (C3-C12)-cycloalkyl; R3 means hydrogen atom, -OH or (C1-C12)-alkyl, or (C1-C12)-alkoxyl, and symbol * means asymmetric carbon atom in form of alkaline metal salt in the amount not exceeding 1 weight% to the total weight of the composition (10 mg/ml) as a photosensitizing agent and a filling agent in an aqueous phase comprising at least a mixture of benzyl alcohol and ethanol or propylene glycol as a solubilizing agent for a photosensitizing agent and a surface-active substance in the amount not exceeding 20 wt.-% to the total mass of the composition under condition that when Cremophore represents a surface-active substance then its amount must not exceed 5 weigh% to the total weight of the composition.
 Means and method for applying photodynamic therapy / 2271801
Method involves applying liposome-enclosed photosensitizer form for administering photodynamic therapy based on sulfonated phthalocyanine of oxyaluminum representing a lipid combination (lecithin and cholesterol) and photosensitizer taken in (14-16)-:1 proportion.
 Stable pharmaceutical preparation of oxaliplatinum for parenteral injection / 2252022
After keeping during pharmaceutically acceptable period oxaliplatinum is placed in transparent, colorless and residue-free solution at concentration of, at least, 7 mg/ml, and a solvent contains sufficient quantity of, at least, one hydroxylated derivative chosen among of 1.2-propandiol, glycerol, maltite, saccharose and inositol. The innovation describes the way to obtain such a preparation. The preparation is stable during pharmaceutically acceptable period of time, that is it remains transparent, colorless and free of any residue within the range of 2-30 C that could be available during its transportation, storage and/or any handling.
 Transesterification method for production of synthetic chlorophyll or bacteriochlorophyll derivatives / 2250905
Invention relates to method for production of synthetic chlorophyll (Chl) or bacteriochlorophyll (Bchl) derivatives of general formula I
 Drug oxaliplatin in the form of a stable aqueous solution, the method of its production and use / 2207857
The invention relates to the preparation on the basis oxaliplatin in the form of a pharmaceutically stable aqueous solution, the method of its production and use
The treatment for psoriasis / 2204392
The invention relates to the field of medicine
Transesterification method for production of synthetic chlorophyll or bacteriochlorophyll derivatives / 2250905
Invention relates to method for production of synthetic chlorophyll (Chl) or bacteriochlorophyll (Bchl) derivatives of general formula I
|
FIELD: medicine. SUBSTANCE: invention concerns medicine, namely oncology and can be used in estimation of clinical effectiveness factors in treatment of carcinoma of cervical stump. Daily urine is analysed for estradiol content and if decreased after treatment from initial level within 8.44-12.85 nmol/days, positive antineoplastic effect of treatment is stated, and if urine estradiol content is maintained in the treated patients within 8.81-11.38 nmol/days, the absence of antineoplastic effect is stated. The obtained results allow considering dynamics of estradiol content in daily urine of the patients suffering from carcinoma of cervical stump prior to AHCT as an additional laboratory test to estimate efficiency of presented pharmacotherapy. Observed positive clinical effect is confirmed by higher operability and improved life quality of the patients. EFFECT: estimation of hormonal index earlier not detected to estimate clinical effectiveness of antineoplastic therapy. 1 tbl, 2 ex
The invention relates to medicine, namely to Oncology, and can be used to determine the factors clinical efficacy of treatment autohemotherapy cancer patients of cervical stump. Cancer cervical stump has a number of peculiarities of clinical course, due to topographic and anatomic disorders in the pelvis, formed after removal of uterine various gynecological diseases. They manifest as disorders of the blood and lymph circulation, offset adjacent uterine organs, which in turn leads to a change in ways of metastasis of the tumor, the rapid involvement of the rectum and bladder. These anatomical features and determine difficulties in the treatment of cancer of this localization, which is more complex than the treatment of cervical cancer. The role of chemotherapy in the treatment of cancer of the cervical stump at present poorly understood. This antitumor effect finds its application only in the form of palliative treatment. This is due to the fact that poorly developed vascular network of tumors of the cervical stump is not possible to ensure it is necessary for the development of the cytotoxic effect of the concentration of chemotherapeutic agents. Insufficient therapeutic adequacy traditionally used the antitumor effects in patients with cervical stump determines the necessity of finding ways and means to increase the effectiveness of treatment in these patients. As one of them suggested carrying out the first stage of complex treatment of patients with cancer of cervical stump chemotherapy. When applied this way to increase the concentration of drugs in the tumor due to their introduction after the preliminary binding to cellular and protein components of blood of the patient in the process of in vitro incubation - autohemotherapy (Sidorenko US, hayrapetov KG, Verkhovtseva A.I., DR. Zlatnik, Jarosinska I.A., nepomnyashaya E.M., Autogame-autohemomagnetotherapy in the treatment of patients with non-Hodgkin's lymphoma. Final scientific researches of the last years of the twentieth century. 2000). The development of malignant process causes many and varied homeostasis in the body-ofwholesale. Among biologically active compounds that support and regulate various kinds of homeostasis in normal and pathological conditions, a special role belongs to the sex hormones. On this basis it is reasonable to search for biochemical tests, reflecting the orientation state changes of the tumor after exposure to chemotherapy (efficacy of chemotherapy), among hormone levels. There is a method of predicting the effectiveness of autohemotherapy cancer patients organs of the oral cavity and pharynx (patent No. 2253354 June 10, 2005). The inventors have identified the relationship of the magnitude of the ratio of the amount of blood concentrations of thyroid hormones (triiodothyronine+thyroxine) to the concentration of pituitary hormone tireotropina patients before the start of neoadjuvant chemotherapy with its immediate effectiveness. However, this method is proposed to predict the clinical effect of drug therapy in patients with malignant tumors of oral mucosa and pharynx and cannot be applied to other localization process. Known "Method of determining the sensitivity of individual patients with ovarian cancer 3-4 degree to chemohormonal" (patent No. 1827639 September 13, 1993), chosen as a prototype. To optimize treatment, the inventors propose to use the ratio of content in the blood of patients with follicle-stimulating and luteinizing hormones and depending on its magnitude predict the sensitivity of the tumor to chemohormonal value ratio less than 1.0) or its absence (if the value is more than 1.0). However, the disadvantage of this method is the possibility of its application only in combination in the treatment of patients with chemo - and hormonal drugs. In addition, the method developed for other genital localization of malignant process, a tie is what it can be used in assessing the effectiveness of drug exposure in patients with cancer of the cervical stump. The aim of the invention is the determination of the efficiency factors of autohemotherapy cancer patients of cervical stump. This goal is achieved by the patients before conducting neoadjuvant autohemotherapy and two weeks after exposure to conventional biochemical method determines the content of the daily urine most active estrogen estradiol. Compare the dynamics of the content of estradiol before and after the course IGHT with the clinical evaluation of the effect of drug therapy on the tumor. Note the presence of a positive clinical effect of neoadjuvant AGHT those of the treated patients, in which the concentration of secreted estradiol ranges 3,30-6,97 nmol/day, and the lack of clinical effect in patients after IGHT retaining the original increased excretion of hormones within concentrations 8,81-11,38 nmol/day. The invention of "a method of evaluating the effectiveness of neoadjuvant autohemotherapy cancer patients of cervical stump" is new, because it is not known from the level of medicine in the field of biochemical research at the determining factors of the clinical effectiveness of treatment autohemotherapy cancer patients of cervical stump. The novelty of the invention lies in the fact that in patients before conducting neoadjuvant autogenocide therapy determine the content of estradiol daily urine and its reduction after treatment from baseline within the boundaries 8,44-12,85 nmol/day state positive antitumor effect of treatment, and for maintaining the treated patients the content of estradiol in urine within the boundaries 8,81-11,38 nmol/day say no antitumor effect. The invention of "a method of evaluating the effectiveness of neoadjuvant autohemotherapy cancer patients of cervical stump is industrially applicable, as it can be reproduced in health care, cancer research institutes, breast care clinics and other medical institutions for the treatment of patients with cancer of the cervical stump. "A method of evaluating the effectiveness of neoadjuvant autohemotherapy cancer patients of cervical stump" as follows: The study included 8 patients with cancer of cervical stump with 2-stage malignant process, the average age of patients amounted to 53.1 years. The diagnosis was established using traditional methods of inspection in the mirror, bimanual and combined vaginal-pryamokishechnye survey, assessing the degree of mobility of the pelvic floor and lookup modern methods of laboratory research. In all patients before conducting IGHT content was determined daily urine estradiol using conventional biochemical method (Brown W. Zancet 1968, No. 3. p.29). All patients with cancer of cervical stump the source level is ü secreted estradiol was elevated compared with healthy women of similar age and ranged 8,44-12,85 nmol/day at the rate 3,49-7,60 nmol/day. Used for IGHT combination of chemotherapeutic agents include cytotoxic drugs cyclophosphamide, cisplatin. Before intravenous cisplatin+cyclophosphamide incubated with the purpose of the blood of the patient for 30 min at 37°C in different bottles. After 2 weeks UGHT before the following stages of complex treatment) were re-determination of the concentration of estradiol in daily urine of patients. At this stage, assessing the clinical effect of drug exposure. When comparing the performance of daily excretion of estradiol before and after IGHT with the results of tumour response to this type of cancer treatment revealed a relationship between dynamics of the hormone content of the treated patients with treatment effectiveness. In 3 of 8 patients (37.5%) of the examination within the specified period after IGHT marked clinical evidence of its effectiveness: reducing the number of abnormal secretions, increase mobility of the pelvic floor, reducing tumor volume, improvement of General condition. The level of estradiol in these patients after treatment was normalized and made from 3,30 to 6,97 nmol/day. The remaining 5 patients course IGHT was not associated with clinical effect, the concentration of estradiol in urine when you study they had increased and fluctuated within 8,81-11,38 nmol/the ut. The obtained results allow to consider the dynamics of the content of estradiol daily urine of cancer patients of cervical stump before and after IGHT as an additional laboratory test to evaluate the effectiveness of this type of drug therapy.
Examples of clinical application "method of evaluating the effectiveness of neoadjuvant autohemotherapy cancer patients of cervical stump". Example 1. Patient M., born in 1950, case history No. 11518/0. Enrolled in the gynecology Department of RNII 31 October 2000 with a diagnosis of cancer of cervical stump, stage III. In 1985, the patient underwent supracervical amputation of the uterus, tubes, 1992 - sided ovariectomy. At the time of admission to hospital with complaints of lower abdominal pain more than 6 months, when there was contact spotting. 1 November 2000 - biopsy of the cervix. Histological analysis of squamous cell carcinoma with keratinization (No. 584056). November 1, 2000, a study of the content of estradiol in daily urine. His concentration was 10,10 nmol/day at normal levels in healthy people from 3,30 to 6,97 nmol/day. November 1, 2000, initiated a comprehensive treatment, the first stage of which was neoadjuvant autohemotherapy drugs platinum (200.0 mg) and cyclophosphamide (800,0 mg). November 14, 2000, a study of the content of estradiol in daily urine. His concentration was 5,87 nmol/l In the same day before he started the m next stage of complex treatment carried out the clinical evaluation of the results of neoadjuvant IGHT. The observed decrease in the number of abnormal secretions, reduced infiltration, increased mobility of the pelvic floor, the reduction of tumor volume. Thus, the decrease in daily urine sick content of estradiol with baseline 10,10 nmol/day to 5.87 nmol/day after IGHT combined with the development of a positive clinical effect of drug exposure. At subsequent stages of complex treatment performed surgical removal of cervical stump, radiation therapy, courses of adjuvant chemotherapy. As of 3 may 2006, the patient is alive without evidence of disease recurrence. Example 2. Patient K., born in 1946 birth, medical history, No. 7084/N. Enrolled in the gynecology Department of RNII 18 may 2001 with a diagnosis of cancer of cervical stump, stage III. When hospitalization complaints spotting observed within 3 months. In 1992 about fibroids implemented supracervical amputation of the uterus without appendages. may 21, 2001, performed a biopsy. The diagnosis is verified, histological analysis of squamous cell carcinoma with keratinization (No. 606122/24). may 21, 2001, the content of estradiol daily urine, the concentration of the hormone was 10,65 nmol/day at the rate 3,30-6,97 nmol/day. may 21, 2001, the first stage of complex treatment of patients received neoadjuvant AGHT the preparation is Tami platinum (150,0 mg) and cyclophosphamide (600,0 mg). June 5, before the next stage of complex treatment retested the level of estradiol in daily urine, its content was br11.01 nmol/day. A clinical evaluation of the results of neoadjuvant OUGHT noted the lack of positive dynamics in motility of the pelvic floor, in the parametrium infiltration and tumor volume, decreased pathological secretions. Thus, the patient against the conservation after neoadjuvant OUGHT initial elevated compared with normal content of estradiol in urine no positive anti-tumor effect. In the course of complex treatment of patients received extirpation of cervical stump, radiation therapy, courses of adjuvant chemotherapy. December 16, 2003, the patient showed a relapse in the vaginal scar. Conducted 6 courses of chemotherapy. Technical and economic efficiency "method of evaluating the effectiveness of neoadjuvant autohemotherapy cancer patients of cervical stump" is the prediction of the clinical effect of autohemotherapy, the determination of hormone levels that were not previously identified to assess the effectiveness of anticancer therapy. The obtained results allow to consider the dynamics of the metric content of estradiol daily urine of cancer patients of cervical stump up and pic the e holding IGHT as an additional laboratory test to evaluate the effectiveness of this type of drug therapy. The presence of a positive clinical effect is confirmed by the increase interoperability, improve the quality of life of patients. A method of evaluating the effectiveness of neoadjuvant autohemotherapy cancer patients of cervical stump, including chemotherapy, biochemical study, characterized in that in patients before conducting neoadjuvant autohemotherapy and 2 weeks after autohemotherapy determine the content of estradiol daily urine and its reduction after treatment from baseline within the boundaries 8,44-12,85 nmol/day state positive antitumor effect of treatment, and for maintaining the treated patients the content of estradiol in urine within the boundaries 8,81-11,38 nmol/day say no antitumor effect.
|
||||||||||||||||||||||||||||
